CD19 and lymphoma: Consistent with their superior anti-lymphoma activity, 7 × 19 CAR-T exhibited enhanced in vivo expansion, longer duration of persistence, and significantly increased recruitment of 7 × 19 CAR-T into tumor sites than anti-CD19 CAR-T cells (Fig. 1k, l; Supplementary Fig. S2b).